New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.
The blood-brain barrier (BBB) presents a major obstacle to the treatment of malignant brain tumors and other central nervous system (CNS) diseases. For this reason, a meeting partially funded by an NIH R13 grant was convened to discuss recent advances and future directions in translational research in neuro-oncology and the BBB. Cell biology and transport across the BBB, delivery of agents to the CNS, neuroimaging, angiogenesis, immunotherapy, and gene therapy, as well as glioma, primary CNS lymphoma, and metastases to the CNS were discussed. Transport across the BBB relates to the neurovascular unit, which consists not only of endothelial cells but also of pericyte, glia, and neuronal elements.
Doolittle
Nancy D
ND
Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA.
Abrey
Lauren E
LE
Bleyer
W Archie
WA
Brem
Steven
S
Davis
Thomas P
TP
Dore-Duffy
Paula
P
Drewes
Lester R
LR
Hall
Walter A
WA
Hoffman
John M
JM
Korfel
Agnieszka
A
Martuza
Robert
R
Muldoon
Leslie L
LL
Peereboom
David
D
Peterson
Darryl R
DR
Rabkin
Samuel D
SD
Smith
Quentin
Q
Stevens
Glen H J
GH
Neuwelt
Edward A
EA
D000970:Antineoplastic Agents; D001692:Biological Transport; D001812:Blood-Brain Barrier / Q000187:drug effects*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D004343:Drug Implants; D006801:Humans; D008279:Magnetic Resonance Imaging; D008495:Medical Oncology; D009462:Neurology
D000970:Antineoplastic Agents; D004343:Drug Implants